2Seventy Bio Inc. has announced a significant regulatory development concerning its common stock. The company plans to delist its shares from Nasdaq and will file a Certification and Notice of Termination of Registration on Form 15 with the U.S. Securities and Exchange Commission $(SEC.UK)$, seeking to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934. This move will also suspend 2Seventy Bio's reporting obligations under Sections 13 and 15(d) of the Exchange Act. The changes follow the company's acquisition by Bristol-Myers Squibb, which has resulted in 2Seventy Bio becoming a wholly-owned subsidiary.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 2Seventy Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-018514), on May 13, 2025, and is solely responsible for the information contained therein.